CJC-1295 and Sermorelin Together: What Is Known
CJC-1295 and Sermorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 13 results, 2 Oct 2026).
Side by side
Showing 5 of 12 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength are the same or both unknown.
| Field | CJC-1295 | Sermorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Also called | CJC, mod GRF, GRF 1-29 | — |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research chemical | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | 4 human (1 randomized or controlled) of 7 summarised | 6 human (1 randomized or controlled) of 9 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 2 mg, 5 mg, 9 mg, 15 mg |
CJC-1295 vs Sermorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
Two GHRH analogues with different persistence
CJC-1295 binds albumin after injection, and one study of it reports a half-life of 8 days.[5]
In that study GH pulses kept their normal frequency and size, while trough GH levels rose 7.5-fold.[5]
For comparison, sermorelin's active fragment GHRH-(1-29), given once daily to prepubertal children with GH deficiency in an open-label trial, took height velocity from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months.[16]
No head-to-head or combined trial
A PubMed search on 2 Oct 2026 for CJC-1295 with sermorelin matched 13 records. The ten shown in the cached results are anti-doping detection methods and sports-medicine reviews.
Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sermorelin[tiab] OR Geref[tiab]); records matched 13; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
One anti-doping study that lists both peptides is a urine metabolism and detection study, not a study of giving them together.[3]
One review notes that most published studies examine therapeutic use under controlled dosing, not the combined protocols common in bodybuilding, and flags cardiovascular strain and insulin resistance as emerging risks.[19]
Regulatory and sport status
A Drugs@FDA search for CJC-1295 returns nothing approved.[20]
FDA's safety note for CJC-1295 also says available clinical data are limited.[21]
WADA's prohibited list names both CJC-1295 and sermorelin as GHRH analogues.[1]
Common questions
CJC-1295 vs sermorelin: which lasts longer?
Only CJC-1295 has a half-life cited here: 8 days in its albumin-binding form, in one study. No sermorelin half-life is cited.[5]
Can you use CJC-1295 and sermorelin together?
The cached PubMed search found no trial of the pair. A review notes that studies mostly test single agents under controlled dosing, not the combined protocols used in bodybuilding.[19]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 6Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 10Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 11Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 12PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 17PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.The Journal of sports medicine and physical fitness · 2026PMID 41880199Accessed 2 Oct 2026
- 20Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 21Official web pageOfficial web page · web page
Found an error? Report a correction.